Ampio CEO Mike Macaluso takes medical leave

  • After almost 10 years in the position
  • Praise for Macaluso
  • Michael Martino taking over temporarily
  • Macaluso said 94 words

(exechange) — Englewood, Colorado, November 22, 2021 — Mike Macaluso, chief executive of Ampio Pharmaceuticals, takes a medical leave of absence. As announced by Ampio Pharmaceuticals Inc. in a news release on Monday, November 22, 2021, Michael (Mike) Macaluso leaves his post as chief executive officer at the biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, after almost 10 years in the role, effective immediately.

Mike Macaluso’s duties as CEO will be taken over temporarily by Michael Martino, a former Acting CEO and Director at HemaFlo Therapeutics Inc., as Interim Chief Executive Officer.

Health reasons

Ampio Pharmaceuticals said: “Mike Macaluso is taking a one-year medical leave of absence from his role as Chairman and CEO, effective immediately. Today’s announcement follows Mr. Macaluso’s disclosure in October, 2021, that he was undergoing medical treatment.”

Share price increase since November 2020

The announcement follows an increase in Ampio Pharmaceuticals Inc.’s share price of 65% since November 2020.

In the position of CEO since 2012

Mike Macaluso became CEO of the Company in 2012.

Michael Macaluso founded DMI Life Sciences Inc. and was a member of the board of directors of DMI Life Sciences Inc., the Company’s predecessor, from its inception until the merger of DMI Life Sciences, Inc. with Chay Acquisitions, Inc., a wholly owned subsidiary of Chay Enterprises, Inc. (together “Chay Enterprises”).

Macaluso has been a member of the Company’s Board since the merger with Chay Enterprises in March 2010, the Company’s CEO since January 2012, and the Chairman of the Company’s Board since May 2010.

In addition, Macaluso has been a member of the board of directors of NASDAQ-listed Aytu BioScience’s (AYTU) since April 2015.

Macaluso was appointed President of Isolagen, Inc. (ILE), which has since been acquired, and served in that position from June 2001 to August 2001, when he was appointed CEO. In June 2003, Macaluso was re-appointed as President of Isolagen, Inc. and served as both CEO and President until September 2004.

Macaluso also served on the board of directors of Isolagen, Inc. from June 2001 until April 2005.

From October 1998 until June 2001, Macaluso was the owner of Page International Communications, a manufacturing business.

Macaluso was a founder and principal of International Printing and Publishing, a position Macaluso held from 1989 until 1997, when he sold that business to a private equity firm.

Push-out Score not determined

When the reason for the departure is health-related, a Push-out Score™ is not determined.

Read the full story in the exechange report 48.2021 ($).